Special CommunicationTransarterial Treatment of Colorectal Cancer Liver Metastases with Irinotecan-Loaded Drug-Eluting Beads: Technical Recommendations
Section snippets
The Panel
The group of physicians, all of whom had considerable experience in the field, included one surgical oncologist and eight interventional radiologists, practicing in different geographical regions (three in North America, one in South America, four in Europe, and one in Australia). The recommendations were collaboratively generated during a meeting held in April 2012.
Patient Selection
The proposed algorithm for the clinical management of patients with liver metastases from CRC is shown in the Figure. Patients who are not candidates for potentially curative treatment may be considered for locoregional therapy with DEBIRI or 90Y radioembolization if they have liver-only or liver-dominant metastatic disease and the level of hepatic parenchymal involvement does not exceed 60%. Liver-dominant metastatic disease is defined as 80% or more of the overall total body metastatic tumor
Final Remarks
The technical recommendations reported here are aimed at ensuring a consistent use of DEBIRI in the treatment of hepatic CRC metastases. However, given the many patient- and tumor-related variables that play a role in the decision-making process, this document is intended as no more than a general guideline. We fully acknowledge that, given the complexity of the disease, individual patient and tumor characteristics may require a different approach with respect to the one recommended here. For
Acknowledgments
The authors thank Research Analysis Library for recording the meeting and providing a draft based on the minutes. Assistance was supported by Biocompatibles UK.
References (21)
- et al.
Hepatic resection for colorectal liver metastases
Surg Clin North Am
(2010) - et al.
Selection for hepatic resection of colorectal liver metastases: expert consensus statement
HPB (Oxford)
(2013) - et al.
Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement
HPB (Oxford)
(2013) - et al.
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial
J Gastrointest Surg
(2012) - et al.
Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review
J Vasc Interv Radiol
(2013) - et al.
Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan
J Vasc Interv Radiol
(2010) - et al.
Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study
HPB (Oxford)
(2010) - et al.
Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe?
HPB (Oxford)
(2011) - et al.
Ultrasound-guided paravertebral block for management of abdominal pain after transarterial embolization using drug-eluting beads loaded with irinotecan
J Vasc Interv Radiol
(2013) - et al.
Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case-control series
HPB (Oxford)
(2013)
Cited by (49)
Survival of Patients with Colorectal Liver Metastases after Transarterial Chemoembolization Using Irinotecan-Eluting Microspheres: A Single-Center Retrospective Analysis Comparing RECIST 1.1 and Choi Criteria
2023, Journal of Vascular and Interventional RadiologyStressing the need for prolonged immediate surveillance after chemoembolization for liver metastases using drug-eluted beads with irinotecan
2020, Diagnostic and Interventional ImagingTranscatheter Embolization of Liver Metastases
2020, Image-Guided Interventions: Expert Radiology Series, Third EditionTransarterial chemoembolisation of colorectal liver metastases with irinotecan-loaded beads: What every interventional radiologist should know
2020, European Journal of Radiology OpenChemoembolization in Conjunction with Bevacizumab: Preliminary Results
2018, Journal of Vascular and Interventional Radiology5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases
2018, Clinics and Research in Hepatology and GastroenterologyCitation Excerpt :All consecutive patients treated with a minimum of one cycle of HAI with 5-FU or mitomycin C at the physician and as decided in the MDT after previous progression or limiting toxicity with HAI of oxaliplatin, from March 2010 to June 2016, were retrospectively enrolled in our database. To be eligible, patients had to have histologically confirmed colorectal adenocarcinoma, exclusive or dominant LM (defined as ≥ 80% of overall total metastatic tumor burden being located in the liver [20] and no clinically active extra-hepatic disease) and no possibility for curative resection assessed by a multidisciplinary team including an experienced surgeon. The dose of HAI of 5-FU ranged from 600 to 1200 mg/m2, and was administered biweekly over 4 hour, while the dose of MMC was 7 mg/m2 and was administered monthly.
R.G.-M. and G.N. are consultants for Biocompatibles UK (Farnham, United Kingdom). W.S.R. is a consultant for Cook (Bloomington, Indiana), B. Braun (Bethlehem, Pennsylvania), and AngioDynamics (Latham, New York), and receives research support from Nordion (Ottawa, Ontario, Canada), Sirtex (North Sydney, Australia), Biocompatibles UK, and B. Braun. None of the other authors have identified a conflict of interest.